Company / Depreciation & Amortization
Akebia Therapeutics, Inc. Depreciation & Amortization History
FY2014-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.7M
FY2022
5-year range
$1.7M / $2.2M
FY2018-FY2022
Trend
-26.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $899,000 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2022 with a 3-year CAGR of +38.9%.
Increased from $899,000 to $2M over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +38.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +38.9%, indicating consistent growth.
- In FY2022, depreciation & amortization decreased 26.3% year-over-year.
- Peak depreciation & amortization was recorded in FY2021.
- Lowest depreciation & amortization in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $1.7M | -26.3% |
| FY2021 | $2.2M | +149.7% |
| FY2020 | $899.0K | +45.7% |
| FY2019 | $617.0K | +108.4% |
| FY2018 | $296.0K | +29500.0% |
| FY2015 | $1.0K | - |
| FY2014 | $0 | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026